Navigation Links
Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease
Date:2/21/2012

LOS ANGELES (Feb. 20, 2012) A Cedars-Sinai research scientist has been awarded two national grants totaling more than $2.5 million, including a prestigious Research Project Grant from the National Institutes of Health to study potential treatments for Alzheimer's disease.

Terrence Town, PhD, is studying drugs that potentially could disrupt the formation and accumulation of sticky amyloid plaques that build up in the brain and are widely considered a root cause of Alzheimer's disease, a chronic and fatal condition that impairs memory and cognition. In the disease's final stages, patients require round-the-clock care.

Amyloid is an abnormal protein usually produced in the bone marrow that can be deposited in any tissue or organ. An unhealthy buildup of the protein is believed to lead to diseases such as Alzheimer's.

"Alzheimer's has the potential to bankrupt this country,'' said Town, PhD, the studies' principal investigator and research scientist in the Cedars-Sinai Regenerative Medicine Institute and the Departments of Biomedical Sciences and Neurosurgery. "It is the public health crisis of our time and the big question is: what are we going to do about it? Our approach is to target the body's immune system to clean up amyloid plaques and thereby allow brain regeneration."

The NIH grant totals more than $2 million over five years and is earmarked for the study of macrophages, common cells that circulate in the blood and are capable of clearing damaging substances, such as plaques.

"Our goal is to identify drugs that give the signal to macrophages to enter the brain and eat away at the amyloid plaque buildup," said Town, the Ben Winters Chair in Regenerative Medicine. "These macrophages have a central mission in life: to eat noxious substances. But because the brain is somewhat shielded from the immune system, peripheral macrophages are given the message not to go into the brain and eat the amyloid plaques. So, if we could identify what's blocking this beneficial response in these cells, the hope is that a drug would enable the macrophages to leave the blood, go into the brain and remove the plaques."

The second grant, for $550,000, was awarded by the American Federation of Aging Research and will enable Town and his team of researchers to study new ways to reduce brain inflammation.

"Understanding this important area of neuroimmunology will likely lead to new therapeutic targets for Alzheimer's,'' Town said.

The author of more than 90 scientific publications, Town is a well-known neuroimmunologist whose research focuses on understanding and treating neurologic disorders including Alzheimer's, viral encephalitis and stroke.

According to the Alzheimer's Association, more than 5.4 million Americans have the disease, and its incidence is on the rise. Alzheimer's destroys brain cells, causing memory, thinking and behavioral problems severe enough to affect work, family and social relationships. It eventually affects the basics of daily living, is incurable and, ultimately, is fatal. Alzheimer's is the sixth-leading cause of death in the United States and the fifth-leading cause for people 65 and older, association statistics show.


'/>"/>

Contact: Sally Stewart
Sally.stewart@cshs.org
310-248-6566
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Moderate red wine drinking may help cut womens breast cancer risk, Cedars-Sinai study shows
2. Cedars-Sinai study: How does a good protein hurt brain cells after clot-induced stroke?
3. TGen and Virginia G. Piper Cancer Center form drug development collaboration with Cedars-Sinai
4. Cedars-Sinai scientists, physicians to be key presenters at World Stem Cell Summit
5. Cedars-Sinai movement disorders expert on international task force for dystonia treatment
6. Latest data from Cedars-Sinai vaccine study supports immune targeting of brain tumors
7. Cedars-Sinais mobile medical clinics receive $500,000 grant from California Community Foundation
8. Cedars-Sinai to hold first annual conference on stem cell therapies for neurological disorders
9. Cedars-Sinais mobile medical clinics receive grant from George Hoag Family Foundation
10. Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies
11. Cedars-Sinai Medical Genetics Institute director honored with lifetime achievement award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, an Indianapolis-based ... standard feature on its secure clinical communication platform. The platform allows clinicians to ... on the type and urgency of a situation. , “We know from ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Therachat , ... new survey in an infographic on the current state of anxiety in support of ... with anxiety, was conducted in April 2017 and benchmarked general anxiety levels as well ...
(Date:5/22/2017)... ... , ... Today, Our Urgent Care celebrates the grand opening of its newest ... Since opening over a month ago, Our Urgent Care Washington has enjoyed serving ... Our Urgent Care walk-in clinic is located at 3195 Phoenix Center Dr., Washington, MO ...
(Date:5/22/2017)... ... May 22, 2017 , ... WeightZone Factor a ... empower WeightZone Factor members to track their exercise patterns, monitor behavioral changes, employ ... all on their mobile phones. It also provides social networks for members with ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pixel Film Studios presents ... use in Final Cut Pro X. The business-oriented elements and dignified animations are ... ProParagraph Corporate will deliver a professional and distinguished look to any multi-line text ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
(Date:5/15/2017)... -- Enterin Inc., a privately-held CNS pharmaceutical company based in ... treat Parkinson,s disease (PD), has enrolled the first patient in ... controlled, multicenter study involving patients with PD and taking place ... a 9-to-12-month period. The first stage is open label and ... sites include Denver , Boca ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
Breaking Medicine Technology: